Results 121 to 130 of about 54,917 (299)
Investigating Cardiovascular Benefits of SGLT2 Inhibitors
Sodium-glucose cotransporter 2 (SGLT2) inhibitors target the proximal tubule where the SGLT2 receptor is located. By blocking the receptor, glucose is forced out of the body through the urine and can no longer reabsorb into the body.
Ostroff, Jared
core +1 more source
Abstract Background Treatment with the sodium‐glucose co‐transporter 2 (SGLT2) inhibitor canagliflozin in insulin dysregulated (ID) horses has shown promising results in randomised clinical trials. Larger field studies are needed to further evaluate treatment responses and potential adverse effects under real‐world conditions.
Moa Hällbom +3 more
wiley +1 more source
Metabolic Communication by SGLT2 Inhibition
BACKGROUND: SGLT2 (sodium-glucose cotransporter 2) inhibitors (SGLT2i) can protect the kidneys and heart, but the underlying mechanism remains poorly understood. METHODS: To gain insights on primary effects of SGLT2i that are not ...
Anja M. Billing +34 more
openaire +3 more sources
Using a 2% salt diet and a 10‐month feeding to model chronic human sodium exposure, we found that black rice improved glucose tolerance and short‐chain fatty acids, but 2% salt inverted black rice's blood glucose benefits. White rice + 2% salt treatment uniquely increased short‐chain fatty acids.
Xiaofang Li +8 more
wiley +1 more source
Research Progress of Berberine in Kidney Disease: Targeting Mitochondria and Ferroptosis
This figure illustrates the model‐specific renoprotective mechanisms of berberine (BBR) across three major kidney diseases. From left to right, the diagram shows that BBR targets distinct core pathways depending on the pathological context: in diabetic nephropathy (DN), BBR activates AMPK to improve mitochondrial energy metabolism; in acute kidney ...
Liuqing Wang +3 more
wiley +1 more source
Geriatric Regenerative Medicine: Mechanisms, Strategies, and Clinical Translation
The pathological drivers of aging—stem cell exhaustion, cellular senescence with SASP, and aged extracellular matrix—are precisely targeted by three corresponding mechanism‐based strategies: stem cell therapies (rejuvenation, regeneration, and replacement), senolytic/senomorphic agents (D + Q, fisetin, vaccines, and CAR‐T), and senescence‐targeting ...
Qiang Li +11 more
wiley +1 more source
SGLT2-is in Acute Heart Failure
Despite the wealth of evidence in favour of SGLT2 inhibitor use in patients with chronic heart failure, their role in the very early stages of heart failure is still unclear. While the latest update of the European Society of Cardiology guidelines on heart failure advocates the use SGLT2 inhibitors in the acute phases of heart failure based on the ...
Matteo Bianco +14 more
openaire +2 more sources
ABSTRACT Background Epicardial adipose tissue (EAT) is a metabolically active fat depot associated with cardiovascular risk and represents a modifiable imaging biomarker. Studies have shown that sodium–glucose cotransporter‐2 (SGLT2) inhibitors reduce EAT thickness in patients with type 2 diabetes mellitus (T2DM). However, it is unclear whether this is
Min Jae Cha +9 more
wiley +1 more source
Introduction: There remains an unmet need to reduce kidney and cardiovascular risk in patients with chronic kidney disease (CKD). This report is therefore intended to provide real-world clinical guidance to primary care providers on sodium-glucose co ...
Anjay Rastogi +7 more
doaj +1 more source
Is GFR decline induced by SGLT2 inhibitor of clinical importance? [PDF]
Background Use of sodium-glucose-cotransporter-2 (SGLT2) inhibitors often causes an initial decline in glomerular filtration rate (GFR). This study addresses the question whether the initial decline of renal function with SGLT2 inhibitor treatment is ...
Bosch, Agnes +6 more
core +1 more source

